European Directorate for the Quality of Medicines and Healthcare. Enquiry: alkyl mesilate (methane sulfonate) impurities in mesilate salts. Pharmeuropa. 2000;12:27.
2.
Committee for Proprietary Medicinal Products (CPMP). Position paper on the limits of genotoxic impurities. London, UK: CPMP; December 18, 2002. CPMP/SWP/5199/02/draft 2.
3.
Committee for Medicinal Products for Human Use (CHMP). Guidelines on the limits of genotoxic impurities. London, UK: CHMP; June 23, 2004. CPMP/SWP/5199/02.
4.
Guidance for industry genotoxic and carcinogenic impurities in drug substances and products: recommended approaches draft. Silver Spring, MD: Center for Drug Evaluation and Research (CDER); December 2008.
5.
MüllerLGockeE. Considerations regarding a permitted daily exposure calculations for ethyl methanesulfonate. Toxicol Lett. 2009;190(3)330-332.
6.
MüllerLGockeELavéTPfisterT. Ethyl methanesulfonate toxicity in Viracept—a comprehensive human risk assessment based on threshold data for genotoxicity. Toxicol Lett. 2009;190(3):317-329.
7.
GockeEMüllerLPfisterT. EMS in Viracept—initial (“traditional”) assessment of risk to patients based on linear dose response relations. Toxicol Lett. 2009;190(3):266-270.
8.
GockeEMüllerL. In vivo studies in the mouse to define a threshold for the genotoxicity of EMS and ENU. Mutat Res. 2009;678(2):101-107.
9.
GockeEBallantyneMWhitwellJMüllerL. MNT and MutaTMMouse studies to define the in vivo dose response relations of the genotoxicity of EMS and ENU. Toxicol Lett. 2009;190(3):286-297.
10.
ICH M7 Concept paper: assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk. Geneva, Switzerland: ICH; June 9, 2010.
